PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Undent	Paperwork Reduction Act of 1995, no	perso	ns are required to resp	ond to a collection of information	on unless it displays a valid OMB control number			
THAU	Substitute for form 1449A/PTO	n 1449A/PTO ATION DISCLOSUR		Complete if Known				
				Application Number	09/944,326			
	INFORMATION DISC	LO	SURE	Filing Date	8/30/2001			
	STATEMENT BY AP	PLI	CANT	First Named Inventor	Gleave et al.			
	(Use as many sheets as nec	essary)	Art Unit	1635			
				Examiner Name	K. A. Lacourciere			
Sheet	1	of	3	Attorney Docket Number	UBC.P-020-2			

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where			
	No.'	Number-Kind Code ² (# Incom)	WIND-00-1111	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
TY		US-6,172,216 B1	1/9/2001	Bennett et al.				
		US-						
		US-						
	<u> </u>	US-						
		US-						
	<u> </u>	US-						
		US-						
		US-						
	L.	US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-			<u> </u>			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۲,
_ 70	,	WO 00/49937	8/31/2000	The University of British Columbia		
		WO 02/22635 A1	3/21/2002	ISIS Pharmaceuticals, Inc.		
	`	WO 03/062421 A1	7/31/2003	The University of British Columbia		
		WO 03/072591 A1	9/4/2003	The University of British Columbia		
·····						
						L

Signature Work	Miramora	Considered	51161	05
*EXAMINER: Initial if reference considers	d, whether or not citation is in conformance with MPEP 609.	Draw line through	citation if not in	conformance and no
considered. Include copy of this foring with	hext communication to applicant. 'Applicant's unique citation	designation number	er (optional) 2 S	ee Kinds Codes of LL

PTO Patent Documents at www.upsto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

continues in completing the form, call 1-800-PTO-9199 and select option 2.

W. . H .

~

PTO/SE/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMR control of the control

IMAUGabstitute for	r form 1449B/PTO				Complete if Known
111505		1001.00		Application Number	09/944,326
INFOH	IMATION D	Application Number 09/944,326 Filing Date 8/30/2001 First Named Inventor Gleave et al. Art Unit 1635 Examiner Name K. A. Lacourciere			
STATI	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Application Number 09/944,326 Filing Date 8/30/2001 First Named Inventor Gleave et al. Art Unit 1635 Examiner Name K. A. Lacourciere				
• • • • • • • • • • • • • • • • • • • •		7314.	Art Unit	1635	
(1	Use <u>as many</u> sheets a	s necessary)		Examiner Name	K. A. Lacourciere
Sheet	2	of	3	Attorney Docket Number	UBC.P-020-2

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1							
		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2 to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58, XP-002262320					
,	•	GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, Page(s) 79-92, Volume 21, XP-001147871					
;	,	GLEAVE ET Al, Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Number 2, XP 009021411					
	,	GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, Page(s) 209-221, Volume 4					
,	,	JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34, XP002262319					
	•	MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both In Vitro and in Vivo, Clinical Cancer Research, 2000, Page(s) 1655-1663, Volume 6, Number 5, Publisher: The American Association for Cancer Research, US, XP000960694					
	,	MIYAKE ET AL., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, 2001, Page(s) 4245-4252, Volume 7					
		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, Page(s) 337-349, Volume 8, Number 7, XP002262321					
	•	ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, Page(s) 633-645, Volume 27, Number 7, XP001002844					
		WILSON ET AL., Clusterin is a secreted mammallan chaperone, TIBS, 2000, Page(s) 95-98, Volume 25, XP 4202536A					
- 	,	WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry,1994, Page(s) 917-925, Volume 227, Number 3, XP 001146404					

		`				
Examiner Signature	Q		inacy	Milamore	Date Considered	Elllas

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

Substitute for form 1449B/PTO	Complete If Known			
	Application Number	09/944,326		
INFORMATION DISCLOSURE	Filing Date	8/30/2001		
STATEMENT BY APPLICANT	First Named Inventor	Gleave et al.		
STATEMENT BY APPLICANT	Art Unit	1635		
(Use as many sheets as necessary)	Examiner Name	K. A. Lacourciere		
Sheet . 3 of 3	Attorney Docket Number	UBC,P-020-2		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
tv	•	ZANGEMEISTER-WITTKE ET AL., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research, 2000, Page(s) 2547-2555, Volume 6, XP-002241562	_
	,	ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2'O-(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental, 2001, Page(s) 934-940, Volume 298, Number 3, XP-002262318	
	,	ZELLWEGER ET AL., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the antiapoptotic Gene Clusterin, Neoplasia, 2001, Page(s) 360-367, Volume 3, Number 4	
_			L
			<u> </u>
Examiner Signature	V	Date Considered 5/16/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Tracy Ann Vivlemore

UBC.P-020-2

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. BAD Stitute for form 1449A/PTO Complete if Known Application Number 09/944,326 INFORMATION DISCLOSURE Filing Date 8/30/2001 First Named Inventor STATEMENT BY APPLICANT Gleave et al. Art Unit (Use as many sheets as necessary) 1635

of

1

i is

Examiner

Signature

2

Sheet

Examiner Name

Attorney Docket Number **U.S. PATENT DOCUMENTS** Name of Patentee or Applicant of Cited Document **Publication Date** Document Number Pages, Columns, Lines, Where Cite Examiner MM-DD-YYYY Relevant Passages or Relevant Initiats' No. Number-Kind Code² (## Figures Appear US-5,040,042 07-08-1997-----Stinehoomb stat US-5,929 040 07-27-1999 wenner et an บระ US-US-US-US-US-US-US-US-US-USus-US-US-US-US-

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code [‡] -Number [‡] - Kind Code [‡] (<i>il known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳٥
	ļ					
					<u> </u>	
						
	ļ					
				<u></u>		├-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of US PTO Patent Documents at www.upsto.gov.or/ MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

monto

Date

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control out

A Rute for	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known			
				Application Number	09/944,326	
INFOR	RMATION DI	SCLOS	SURE	Filing Date	or 09/944,326 8/30/2001 Or Gleave et al. 1635 Tracy Ann Vivlemore	
STATI	Application Number 09/944,326					
(Use as many sheets as necessary)				Examiner Name	Tracy Ann Vivlemore	
Sheet	2	of	2	Attorney Docket Number	UBC.P-020-2	

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AGRAWAL ET AL., Antisense Therapeutius-is-it as simple as complementary buso recognition, Molecular Medicine Teday, 2000, Page(e) 72-81, Volume 6, Publisher: Elsevier Science Ltd.	
-	ANDREA D. BRANCH, A good antisense melecule is hard to find JH3S, 1998, Page(s) 45-60, Publisher: Elsovier Science-Ltd.	
 	CROOKE ET AL., Basic Principles of Antisonse Therapeutics, Antisense Research and Application, 2004, Page(s) 1 50, Publisher Springer.	
_	SEN ET AL., Suppression of Sene Expression by Targeted Disruption of Messenger RNA. Available Options and Surrent Strategies, Stem Cells 2000, 2000, Page(s) 397-319, Volume 18.	
	OPAENSKA ET AL., Nucleic acid therapoutics. Basic principles and recent applications, Nature Reviews, 2000, Page(s) 503-514, Volume 1	
 -		-
	· ·	1

	$\overline{}$	<u> </u>			
Examiner Signature	Q	mant	O Probranto	Date Cassidered	5/16/05
ACVALUNCO.	Initial if an	farance considered	Abothor or not election to be conformed	AND THE PROPERTY OF THE PARTY O	ala attachan ti ana ta ana farana ana ana

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.